Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc (NQ: CMND )

1.190 +0.050 (+4.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Clearmind Medicine Inc

< Previous 1 2 3 4 5 6 Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We have all of the biggest pre-market stock movers that traders need to know about on Friday with the latest news breakdowns! 
Via InvestorPlace
Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Nasdaq Edges Lower; Morgan Stanley Earnings Top Views
Via Benzinga
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Crude Oil Down 1%; Bank of America Posts Upbeat Earnings
Via Benzinga
Exposures Fossil Fuels
Why Is SciSparc (SPRC) Stock Up 25% Today?
SciSparc stock is up on Tuesday as SPRC investors learn of the company filing a new patent covering its weight loss treatment. 
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Dow Jumps 400 Points; US Retail Sales Flat For June
Via Benzinga
Topics Stocks
Exposures US Equities
Why Psychedelic-Pharma Clearmind Medicine Stock Is Moving Higher
Clearmind Medicine shares are trading higher Friday after the company announced advancement in its proprietary MEAI-based binge behavior regulator program through the granting of patent approval in... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Day Trading My Way From Red To Green
I set daily profit goals and max loss limits to manage my risk. My daily goal is $5,000, and I cap my daily loss at the same amount. 
Via Talk Markets
CMND Stock Earnings: Clearmind Medicine Reported Results for Q2 2024
Clearmind Medicine just reported results for the second quarter of 2024. 
Via InvestorPlace
What's Going On With Clearmind Medicine Stock Tuesday?
Clearmind said its alcohol substitute was granted patents in the U.S., India and Europe. The company also highlighted that the no/low alcohol category is forecasted to grow at a volume CAGR of more... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Clearmind Medicine Stock Is Moving Higher
Clearmind Medicine shares are up Tuesday after the company announced it signed an exclusive patent licensing agreement with Yissum Research Development. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Via Benzinga
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Via Benzinga
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
Via Benzinga
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Via Benzinga
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
Via Benzinga
Topics Economy
Exposures Interest Rates
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose sharply in today’s pre-market trading after the company reported a year-over-year increase in FY23 EPS results. 
Via Benzinga
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
Via Benzinga
Podcast: Clearmind's Non-Hallucinogenic Psychoactive Molecule Could Become A Solution For Addictive Behaviors
Via Benzinga
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Via Benzinga
EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds
Patent applications by Clearmind Medicine for novel compositions in collaboration with SciSparc. Clearmind's CEO, highlights the significant expansion of IP protection. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Next-Gen Psychedelics Companies SciSparc And Clearmind Collaboration File 3 Patents
SciSparc & Clearmind file patents for LSD, psilocybin, DMT blends, advancing psychedelic therapeutics for mental health. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
What's Going On With Psychedelic Drug-Developers SciSparc And Clearmind Stock?
SciSparc Ltd. and Clearmind Medicine Inc. shares are trading higher Tuesday after the companies announced the submission of three international patent applications as part of the ongoing collaboration... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
Via Benzinga
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
Via Benzinga
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian... 
Via Benzinga
Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and online course available. 
Via Benzinga
Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.